Handling of allergen immunotherapy in the COVID‐19 pandemic: An ARIA‐EAACI statement

Handling of allergen immunotherapy in the COVID‐19 pandemic: An ARIA‐EAACI statement


Authors: Ludger Klimek  Marek Jutel  Cezmi Akdis  Jean Bousquet  Mübeccel Akdis  Claus Bachert  Ioana Agache  Ignacio Ansotegui  Anna Bedbrook  Sinthia Bosnic‐Anticevich  Giorgio W Canonica  Tomas Chivato  Alvaro A Cruz  Wiencyslawa Czarlewski  Stefano Del Giacco  Hui Du  Joao A Fonseca  Yadong Gao  Tari Haahtela  Karin Hoffmann‐Sommergruber  Juan‐Carlos Ivancevich  Nikolai Khaltaev  Edward F Knol  Piotr Kuna  Desiree Larenas‐Linnemann  Erik Melen  Joaquim Mullol  Robert Naclerio  Ken Ohta Yoshitaka Okamoto  Liam O’Mahony  Gabrielle L Onorato  Nikos G Papadopoulos  Ruby Pawankar Oliver Pfaar  Boleslaw Samolinski  Jurgen Schwarze  Sanna Toppila‐Salmi  Mohamed H. Shamji  Maria Teresa Ventura  Arunas Valiulis  Arzu Yorgancioglu  Paolo Matricardi  Torsten Zuberbier  The ARIA‐MASK study group

Abstract
The current COVID‐19 pandemic influences many areas of social life, medical treatments and the way allergy is performed. Allergen‐specific immunotherapy (AIT) is one of the most important treatment options for IgE‐mediated allergies and is based on immunological effects on the diseased patient


Doi: 10.1111/all.14336

Comentarios

Entradas populares de este blog

ICON: Diagnosis and management of allergic conjunctivitis. Miércoles 25 de marzo

Instructivo para la vigilancia en salud pública intensificada de infección respiratoria aguda asociada al nuevo coronavirus 2019 (COVID-19).

BCG Vaccination Enhances the Immunogenicity of Subsequent Influenza Vaccination in Healthy Volunteers: A Randomized, Placebo-Controlled Pilot Study. Martes 14 de abril